Synaptixbio sets off on quest to find therapy for rare CNS disease

Updated: Dec 16, 2021

U.K.’s Synaptixbio Ltd. has launched, aiming to tackle a rare and often fatal disease of the central nervous system (CNS), TUBB4a leukodystrophy.

To continue reading please go to the article on BioWorld

7 views0 comments

Recent Posts

See All

Dr Dan Williams, CEO and Co-Founder of new biotech business SynaptixBio, discusses how the search is on to find the first treatment for one of the world’s rarest diseases, TUBB4A-associated leukodystr

SynaptixBio, an Oxford, UK-based research company, has been launched by a worldwide team of medical and pharmaceutical scientists to develop the world’s first disease modifying treatment for leukodyst